$1.28
-0.10[-7.25%]
At close: Apr 25
$1.28
0[0.00%]
After Hours: 5:15PM EDT
Nektar Therapeutics
(NASDAQ:NKTR)Nektar Therapeutics Stock (NASDAQ:NKTR), Analyst Ratings, Price Targets, Predictions
Nektar Therapeutics has a consensus price target of $6.57, established from looking at the 28 latest analyst ratings. The last 3 analyst ratings were released from Jefferies, JP Morgan, and TD Cowen on March 6, 2024, November 20, 2023, and November 9, 2023. With an average price target of $0.33 between Jefferies, JP Morgan, and TD Cowen, there's an implied -73.96% downside for Nektar Therapeutics from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Jefferies
JP Morgan
TD Cowen
Mizuho
Oppenheimer
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Nektar Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/06/2024 | NKTR | Buy Now | Nektar Therapeutics | $1.28 | -21.88% | Jefferies | Roger Song | $0.5 → $1 | Maintains | Hold | Get Alert |
| 11/20/2023 | NKTR | Buy Now | Nektar Therapeutics | $1.28 | — | JP Morgan | Jessica Fye | — | Reinstates | → Underweight | Get Alert |
| 11/09/2023 | NKTR | Buy Now | Nektar Therapeutics | $1.28 | — | TD Cowen | Chris Shibutani | — | Upgrade | Market Perform → Outperform | Get Alert |
| 08/07/2023 | NKTR | Buy Now | Nektar Therapeutics | $1.28 | 368.75% | Mizuho | Mara Goldstein | → $6 | Reiterates | → Neutral | Get Alert |
| 05/10/2023 | NKTR | Buy Now | Nektar Therapeutics | $1.28 | -21.88% | Jefferies | Roger Song | $1.5 → $1 | Upgrade | Underperform → Hold | Get Alert |
| 03/06/2023 | NKTR | Buy Now | Nektar Therapeutics | $1.28 | 134.38% | Oppenheimer | Jay Olson | $5 → $3 | Maintains | Perform | Get Alert |
| 02/27/2023 | NKTR | Buy Now | Nektar Therapeutics | $1.28 | 56.25% | Goldman Sachs | Chris Shibutani | $3 → $2 | Maintains | Sell | Get Alert |
| 02/24/2023 | NKTR | Buy Now | Nektar Therapeutics | $1.28 | 134.38% | SVB Leerink | Daina Graybosch | $5 → $3 | Maintains | Market Perform | Get Alert |
| 02/24/2023 | NKTR | Buy Now | Nektar Therapeutics | $1.28 | 17.19% | Jefferies | Roger Song | $3.2 → $1.5 | Downgrade | Hold → Underperform | Get Alert |
| 08/08/2022 | NKTR | Buy Now | Nektar Therapeutics | $1.28 | — | JP Morgan | Jessica Fye | — | Downgrade | Neutral → Underweight | Get Alert |
| 05/31/2022 | NKTR | Buy Now | Nektar Therapeutics | $1.28 | 212.5% | Jefferies | Roger Song | $12 → $4 | Assumes | → Hold | Get Alert |
| 04/18/2022 | NKTR | Buy Now | Nektar Therapeutics | $1.28 | 368.75% | Mizuho | Mara Goldstein | $8 → $6 | Maintains | Neutral | Get Alert |
| 04/18/2022 | NKTR | Buy Now | Nektar Therapeutics | $1.28 | 134.38% | Goldman Sachs | Chris Shibutani | → $3 | Downgrade | Neutral → Sell | Get Alert |
| 04/18/2022 | NKTR | Buy Now | Nektar Therapeutics | $1.28 | 368.75% | SVB Leerink | Daina Graybosch | $7 → $6 | Maintains | Market Perform | Get Alert |
| 03/16/2022 | NKTR | Buy Now | Nektar Therapeutics | $1.28 | 368.75% | Canaccord Genuity | Arlinda Lee | $25 → $6 | Maintains | Buy | Get Alert |
| 03/15/2022 | NKTR | Buy Now | Nektar Therapeutics | $1.28 | — | BTIG | Robert Hazlett | — | Downgrade | Buy → Neutral | Get Alert |
| 03/15/2022 | NKTR | Buy Now | Nektar Therapeutics | $1.28 | 446.88% | SVB Leerink | Daina Graybosch | $18 → $7 | Maintains | Market Perform | Get Alert |
| 03/15/2022 | NKTR | Buy Now | Nektar Therapeutics | $1.28 | 525% | Mizuho | Mara Goldstein | $35 → $8 | Downgrade | Buy → Neutral | Get Alert |
| 03/15/2022 | NKTR | Buy Now | Nektar Therapeutics | $1.28 | — | Cowen & Co. | Boris Peaker | — | Downgrade | Outperform → Market Perform | Get Alert |
FAQ
What is the target price for Nektar Therapeutics (NKTR)?
The latest price target for Nektar Therapeutics (NASDAQ: NKTR) was reported by Jefferies on March 6, 2024. The analyst firm set a price target for $1.00 expecting NKTR to fall to within 12 months (a possible -21.88% downside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Nektar Therapeutics (NKTR)?
The latest analyst rating for Nektar Therapeutics (NASDAQ: NKTR) was provided by Jefferies, and Nektar Therapeutics maintained their hold rating.
When was the last upgrade for Nektar Therapeutics (NKTR)?
The last upgrade for Nektar Therapeutics happened on November 9, 2023 when TD Cowen raised their price target to N/A. TD Cowen previously had a market perform for Nektar Therapeutics.
When was the last downgrade for Nektar Therapeutics (NKTR)?
The last downgrade for Nektar Therapeutics happened on February 24, 2023 when Jefferies changed their price target from $3.2 to $1.5 for Nektar Therapeutics.
When is the next analyst rating going to be posted or updated for Nektar Therapeutics (NKTR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nektar Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nektar Therapeutics was filed on March 6, 2024 so you should expect the next rating to be made available sometime around March 6, 2025.
Is the Analyst Rating Nektar Therapeutics (NKTR) correct?
While ratings are subjective and will change, the latest Nektar Therapeutics (NKTR) rating was a maintained with a price target of $0.50 to $1.00. The current price Nektar Therapeutics (NKTR) is trading at is $1.28, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.